search
Back to results

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

Primary Purpose

Non-erosive Reflux Disease

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
YYD601 20mg
Nexium 20mg
Placebos
Sponsored by
Yooyoung Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-erosive Reflux Disease

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A man or woman over 20 years old less than 70 years old.
  • A man or woman who has below all characters and diagnosis as NERD.

    1. A man or woman who has experienced symptom(hearburn or/and acid regurgitation) over 3month at least.
    2. A man or woman who has experienced symptom(heartburn or/and acid regurgitation) within 7days before Visit1, meet below 1) or 2) criteria.

      ** Symptom (heartburn and acid regurgitation) is confirmed by RDQ

      • Experienced above 2 days in a week, heartburn of acid regurgitation above the weakness.
      • Experienced above 1 day in a week, heartburn of acid regurgitation above the middle.
    3. A man or woman who has been made diagnosis as LA grade0(Zero) measured through the dendoscopy which is corried out within 14 days, there is no observed muscosal break.
  • A man or woman who has a full understanding of this clinical trial through the detailed explanation, agree in writing to participate in this trial.

Exclusion Criteria:

  • Who has hyper sensitivity reaction about other drugs, ingredients, components of investigator product or compound of benzimidazole.
  • Who has ERD.
  • Who get a diagnosis as a IBS within the last 3 months.
  • Who have taken drugs about reflux esophagitis (H₂-receptor inhibitor (H2RA) Prostaglandin(PG), Antacid, Prokinetic acid etc.) above 2 times as an usual dose. (* refer to the Concomitant medication in text.)
  • Who havbe taken gastric acid secretion inhibitors including PPIs within 2 weeks before the endoscopy.
  • Who has been experienced the disease affecting the esophagus(Eosinophilic esophagitis, esophageal varices, cirrhosis, Virus or Fungal infection, Esophageal stricture, primary esophageal motility disorder and gastrointestinal bleeding). Or who has a history of radio therapeutics, freeze treatment about the esophagus.
  • Who has the gastric or duodenal ulcer, Zollinger-Ellison and other acid hypersecretory condition been experienced.
  • Who has hyper-sensitivity, reaction about PPIs (ex. Lansoprazole, omeprazole, rabeprazole, pantoprazole or esomeprazole).
  • Who has gotten a diagnosis as a cancer within 5 years before participated in this clinical trail (expect the basal cell on the skin), peptic ulcer or benign tumor.

Sites / Locations

  • Korea University Ansan Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

YYD601 20mg

Nexium 20mg

Arm Description

Esomeprazole magnesium Dihydrate.

Esomeprazole magnesium trihydrate, a substituted benzimidazole.

Outcomes

Primary Outcome Measures

Recovered percentage(%) of the symptom
Recovered percentage(%) of the symptom(heartburn or/and acid regurgitation) measured by RDQ after administration(baseline).
Change of the score about the symptom
Change of the score about the symptom(heartburn or/and acid regurgitation) measured by RDQ after administration(baseline).
Percentage(%) of the patients who have symptom during the daytime
Percentage(%) of the patients who have symptom(heartburn or/and acid regurgitation) during the daytime measured by Patients diary after administration(baseline).
Percentage(%) of the patients who have symptom during the nighttime
Percentage(%) of the patients who have symptom(heartburn or/and acid regurgitation) during the nighttime measured by Patients diary after administration(baseline).
Percentage(%) of the days no symtom
Percentage(%) of the days no symptom(heartburn or/and acid regurgitation) among the patients who have symptom(heartburn or/and acid regurgitation) during the nighttime measured by Patients diary after administration(baseline).

Secondary Outcome Measures

Full Information

First Posted
May 27, 2019
Last Updated
May 7, 2021
Sponsor
Yooyoung Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03967886
Brief Title
Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients
Official Title
A Randomized, Double-blind, Placebo-controlled, Multi-centers Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients (Phase3).
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
April 10, 2019 (Actual)
Primary Completion Date
December 20, 2019 (Actual)
Study Completion Date
May 27, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yooyoung Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients
Detailed Description
This Phase 3 Clinical Trial is Designed as Randomized, Double-blind, Placebo-controlled, Multi-centers Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients (Phase3).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-erosive Reflux Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Arm Title
YYD601 20mg
Arm Type
Experimental
Arm Description
Esomeprazole magnesium Dihydrate.
Arm Title
Nexium 20mg
Arm Type
Active Comparator
Arm Description
Esomeprazole magnesium trihydrate, a substituted benzimidazole.
Intervention Type
Drug
Intervention Name(s)
YYD601 20mg
Intervention Description
Patients should take drugs an hour before breakfast.
Intervention Type
Drug
Intervention Name(s)
Nexium 20mg
Intervention Description
Patients should take drugs an hour before breakfast.
Intervention Type
Drug
Intervention Name(s)
Placebos
Intervention Description
The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
Primary Outcome Measure Information:
Title
Recovered percentage(%) of the symptom
Description
Recovered percentage(%) of the symptom(heartburn or/and acid regurgitation) measured by RDQ after administration(baseline).
Time Frame
within 4 weeks
Title
Change of the score about the symptom
Description
Change of the score about the symptom(heartburn or/and acid regurgitation) measured by RDQ after administration(baseline).
Time Frame
within 4 weeks
Title
Percentage(%) of the patients who have symptom during the daytime
Description
Percentage(%) of the patients who have symptom(heartburn or/and acid regurgitation) during the daytime measured by Patients diary after administration(baseline).
Time Frame
within 4 weeks
Title
Percentage(%) of the patients who have symptom during the nighttime
Description
Percentage(%) of the patients who have symptom(heartburn or/and acid regurgitation) during the nighttime measured by Patients diary after administration(baseline).
Time Frame
within 4 weeks
Title
Percentage(%) of the days no symtom
Description
Percentage(%) of the days no symptom(heartburn or/and acid regurgitation) among the patients who have symptom(heartburn or/and acid regurgitation) during the nighttime measured by Patients diary after administration(baseline).
Time Frame
within 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A man or woman over 20 years old less than 70 years old. A man or woman who has below all characters and diagnosis as NERD. A man or woman who has experienced symptom(hearburn or/and acid regurgitation) over 3month at least. A man or woman who has experienced symptom(heartburn or/and acid regurgitation) within 7days before Visit1, meet below 1) or 2) criteria. ** Symptom (heartburn and acid regurgitation) is confirmed by RDQ Experienced above 2 days in a week, heartburn of acid regurgitation above the weakness. Experienced above 1 day in a week, heartburn of acid regurgitation above the middle. A man or woman who has been made diagnosis as LA grade0(Zero) measured through the dendoscopy which is corried out within 14 days, there is no observed muscosal break. A man or woman who has a full understanding of this clinical trial through the detailed explanation, agree in writing to participate in this trial. Exclusion Criteria: Who has hyper sensitivity reaction about other drugs, ingredients, components of investigator product or compound of benzimidazole. Who has ERD. Who get a diagnosis as a IBS within the last 3 months. Who have taken drugs about reflux esophagitis (H₂-receptor inhibitor (H2RA) Prostaglandin(PG), Antacid, Prokinetic acid etc.) above 2 times as an usual dose. (* refer to the Concomitant medication in text.) Who havbe taken gastric acid secretion inhibitors including PPIs within 2 weeks before the endoscopy. Who has been experienced the disease affecting the esophagus(Eosinophilic esophagitis, esophageal varices, cirrhosis, Virus or Fungal infection, Esophageal stricture, primary esophageal motility disorder and gastrointestinal bleeding). Or who has a history of radio therapeutics, freeze treatment about the esophagus. Who has the gastric or duodenal ulcer, Zollinger-Ellison and other acid hypersecretory condition been experienced. Who has hyper-sensitivity, reaction about PPIs (ex. Lansoprazole, omeprazole, rabeprazole, pantoprazole or esomeprazole). Who has gotten a diagnosis as a cancer within 5 years before participated in this clinical trail (expect the basal cell on the skin), peptic ulcer or benign tumor.
Facility Information:
Facility Name
Korea University Ansan Hospital
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients

We'll reach out to this number within 24 hrs